Cutaneous and Ganglion Sarcoidosis Induced by Polycaprolactone Facial Filler: A New Expression of ASIA Syndrome?
Authors:
Open Access
- 9 June 2021
- journal article
- research article
- Published by SMC Media in European Journal of Case Reports in Internal Medicine
- Vol. 8 (6) , 002652
Abstract
Dermal fillers are applied using a minimally invasive technique with a good safety profile. However, they can have side effects. We present the case of a patient who, 2 months after undergoing polycaprolactone (Ellansé®) injections, developed nodular facial and nodal lesions that were compatible with sarcoidosis on histology. This complication has not been previously described for polycaprolactone and could be the expression of an autoimmune syndrome induced by adjuvants.Keywords
This publication has 5 references indexed in Scilit:
- Polycaprolactone‐based dermal filler complications: A retrospective study of 1111 treatmentsJournal of Cosmetic Dermatology, 2020
- Interleukin-36γ–producing macrophages drive IL-17–mediated fibrosisScience Immunology, 2019
- Cutaneous SarcoidosisClinics in Chest Medicine, 2015
- Human adjuvant-related syndrome or autoimmune/inflammatory syndrome induced by adjuvants. Where have we come from? Where are we going? A proposal for new diagnostic criteriaLupus, 2015
- Complications of minimally invasive cosmetic procedures: Prevention and managementJournal of Cutaneous and Aesthetic Surgery, 2012